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Carrier frequency of the GJB2 mutations that cause
hereditary hearing loss in the Japanese population
Mirei Taniguchi1, Hirotaka Matsuo2, Seiko Shimizu2, Akiyoshi Nakayama2, Koji Suzuki3, Nobuyuki Hamajima4,
Nariyoshi Shinomiya2, Shinya Nishio5, Shinji Kosugi6, Shin-ichi Usami5, Juichi Ito1 and Shin-ichiro Kitajiri1
Hearing impairment is one of the most common sensory disorders that affect ~1 in 1000 children, and half of them are
considered to be hereditary. Information about the carrier frequencies of mutations that underlie autosomal recessive disorders is
indispensable for accurate genetic counseling to predict the probability of patients’ children’s disease. However, there have been
few reports speciﬁc to the Japanese population. GJB2 mutations are reported to be the most frequent cause of hereditary hearing
loss, and the mutation spectrum and frequency of GJB2 mutations were reported to vary among different ethnic groups. In this
study, we investigated the carrier frequency of GJB2 mutations and the mutation spectrum in 509 individuals randomly selected
from the general Japanese population. We show that the carrier frequencies of the two most common pathogenic mutations are
1.57% (8/509) for c.235delC and 1.77% (9/509) for p.Val37Ile. In addition to these mutations, we found two pathogenic
variants (p.[Gly45Glu;Tyr136*] and p.Arg143Trp), and the total carrier frequency was estimated to be around 3.73% (19/509).
We also detected six unclassiﬁed variants, including two novel variants (p.Cys60Tyr and p.Phe106Leu), with the former predicted
to be pathogenic. These ﬁndings will provide indispensable information for genetic counseling in the Japanese population.
Journal of Human Genetics (2015) 60, 613–617; doi:10.1038/jhg.2015.82; published online 16 July 2015
INTRODUCTION
Inherited diseases are frequently found worldwide and a major group
of inherited diseases is autosomal recessive disorders such as
non-syndromic hereditary hearing impairment, Fukuyama congenital
muscular dystrophy, Wilson disease and xeroderma pigmentosum.
The carrier frequencies of these diseases are estimated to be 0.9% for
Fukuyama congenital muscular dystrophy,1 1.1% for Wilson disease2
and 0.9% for xeroderma pigmentosum (see the Japan Intractable
Disease Information Center’s website: http://www.nanbyou.or.jp/
entry/112). The mutation spectrum of these diseases is reported to
be population speciﬁc.1,3 Among these autosomal recessive disorders,
non-syndromic congenital hearing impairment is reported to be the
most frequent.4–6 Approximately 1 in 1000 new-born children are
affected by congenital hearing impairment, and 50–60% cases of them
are attributable to genetic causes.7 Hereditary hearing loss has
considerable genetic heterogeneity and, to date, more than 100 genetic
loci have been discovered to be the cause.8 Genetic testing for
congenital hearing impairment has become more important for
accurate diagnoses, prediction of severity of hearing loss, estimation
of associated abnormalities, selection of appropriate habilitation
options, prevention of hearing loss and better genetic counseling.9
Recently, the panel screening of multiple mutations by invader assay10
was reported to be very efﬁcient.9 Genetic testing by invader assay is
now performed throughout Japan, and the Japanese National Health
Insurance began to cover its costs from April 2012. Currently, hearing-
impaired patients can easily access clinical diagnostic screening by
genetic testing, which should be accompanied by the appropriate
genetic counseling that includes an estimation of the next generation’s
incidence (or recurrence) of hearing difﬁculty.
Most hereditary impairment is caused by recessive mutations in
genes such as GJB2 and SLC26A4.7 In the case of autosomal recessive
disorders, patients have mutations in both the paternal and maternal
alleles. Therefore, to estimate the next generation’s incidence ratio,
the carrier frequencies of the mutations in these genes must be
ascertained. However, there are only a limited number of reports
about the carrier frequencies of autosomal recessive disorders, such as
hearing impairment, in the Japanese population.5,6
The GJB2 gene is the most prevalent for congenital hearing loss11,12
and the mutation spectrums are known to vary among different ethnic
groups.6 It is vital to study the carrier frequency and mutation
spectrum of each genetic background to enable more precise genetic
counseling. The GJB2 gene encodes connexin26, a member of the
connexin family of proteins that are constituents of the intercellular
gap junction.13 The ﬁrst GJB2 mutation was reported by Kelsell et al.
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in 199714 and since then more than 100 pathogenic variants have been
reported worldwide (see the Connexin-deafness website: http://
davinci.crg.es/deafness/). In a previous report, GJB2 mutations were
estimated to be responsible for about 15–20% of the cases of deafness7
in the US, and 12.5% (33/264) of those in Japan.9 The c.35delG
mutation is the most common in the Caucasian population, and
the c.235delC and p.Val37Ile mutations are the most prevalent in the
Asian population.6,15 The carrier frequency of GJB2 mutations in the
control population is reported to be 2–4%15–17 in the US, in Europe,
and in Korea, but the carrier frequency in the Japanese population has
not yet been reported. The information about both the carrier
frequency and spectrum with respect of GJB2 mutations in Japan is
very important because GJB2 mutations were reported to have a
phenotype–genotype correlation.18,19
The purpose of this study is to investigate the carrier frequency
of GJB2 mutations and the mutation spectrum in the Japanese
population to provide more accurate information for genetic counsel-
ing. This is the ﬁrst study in Japan to estimate the carrier frequency of
the GJB2 mutations causing hereditary hearing loss, the most frequent
autosomal recessive disorder in Japan.
SUBJECTS AND METHODS
Experiments were approved by the Kyoto University Graduate School and
Faculty of Medicine, Ethics Committee (Permit number: G294), and written
informed consent was obtained from each participant prior to genetic
analysis. Blood samples were collected from 509 healthy Japanese
people (201 males and 308 females) at annual health checks in Yakumo,
Hokkaido in Japan. Their ages ranged from 40 to 91 years, and the average
was 67.8 years. According to the questionnaire ﬁlled in by the subjects,
56/509 (11.0%) had subjectively experienced hearing difﬁculty, and in terms of
vestibular function, 106/509 (20.8%) had experienced vertigo or dizziness.
From the blood sample, we measured HbA1c (NGSP; National Glycohemo-
globin Standardization Program) levels and 36 out of 509 people (7.1%) were
over 6.5, revealing a risk of diabetes, which is compatible with Japanese general
population. The result from our questionnaire are consistent with Japan Trak
report in which 10.8% of the randomly selected 15 036 respondents reported
experiencing hearing difﬁculty (see the Japan Trak website: http://www.atpress.
ne.jp/view/32264). Therefore, the subjects enrolled in this study are thought to
be representative of the population in Japan.
To identify GJB2 mutations, a fragment containing the entire coding region
were ampliﬁed from genomic DNA sample by PCR using the primer pair
5ʹ-GGTGAGGTTFTFTAAGAGTTGG-3ʹ/5ʹ-CTACGGTGTTACTCGAGACGA-3ʹ,
and the amplicon were used as a template for direct sequencing.5 Direct
sequencing analysis was performed using an ABI PRISM Genetic Analyzer
(Applied Biosystems, Waltham, MA, USA), and the data were analyzed using ABI
Variant Reporter v1.1 (Applied Biosystems).
RESULTS
Table 1 summarizes the variants identiﬁed in this study. Among the
mutations screened by the invader assay,9 which are covered by
Japanese health insurance, we found six previously reported patho-
genic variants within the coding region of GJB2. In detail, we detected
Table 1 GJB2 variants detected in 509 Japanese people
Codon Nucleotide Heterozygote Homozygote
Frequency of mutant
alleles (n=1018)




p.T8M c.23C4T 2 0 0.20% 2 (0.39%) Unproven pathogenic
nature
Kenna et al.26
p.G12fsa c.35delG 0 0 0 0 Pathogenic Denoyelle et al.,28 Estivill
et al.22
p.V27I c.79G4A 235 71 37.00% 306 (60.12%) Not pathogenic Zelante et al.,11 Abe et al.5





1 0 0.10% 1 (0.20%) Pathogenic Fuse et al.20
p.L56fs c.167delT 0 0 0 0 Pathogenic Zelante et al.11
p.C60Y c.179G4A 1 0 0.10% 1 (0.20%) Unproven pathogenic
nature
This study
p.V63V c.189G4T 1 0 0.10% 1 (0.20%) Not pathogenic
(silent variation)
This study
p.I71Ta,b c.212T4C 1 0 0.10% 1 (0.20%) Unproven pathogenic
nature
Ohtsuka et al.6
p.L79fsa c.235delC 8 0 0.79% 8 (1.57%) Pathogenic Fuse et al.,20 Abe et al.5
p.F106L c.318C4A 1 0 0.10% 1 (0.20%) Unproven pathogenic
nature
This study
p.R127H c.380G4A 1 0 0.10% 1 (0.20%) Unproven pathogenic
nature
Estivill et al.,22 Roux
et al.27
p.E114G c.341A4G 118 8 13.20% 126 (24.75%) Not pathogenic Green et al.,15 Fuse et al.20
p.T123Na c.368C4A 6 0 0.59% 6 (1.18%) Not pathogenic Park et al.,30 Abe et al.,5
Ohtsuka et al.6
p.R143Wa c.427C4T 1 0 0.10% 1 (0.20%) Pathogenic Brobby et al.,31
p.F191La,b c.570T4C 1 0 0.10% 1 (0.20%) Unproven pathogenic
nature
Ohtsuka et al.6
p.I203T c.608T4C 55 1 5.60% 56 (11.0%) Not pathogenic Kudo et al.,21 Abe et al.5
We detected nine pathogenic mutant alleles that had p.V37I, eight c.235delC, one p.[G45E;Y136X] and one p.R143W. We also detected two p.T8M, one p.I71T, one p.R127H and one p.F191L
mutation, the pathogenesis of which had not been proven. GJB2 carrier frequency in Japanese people was estimated to be 19/509 (3.73%).
aMutations screened by Invader assay covered by the Japanese National Health Insurance (Abe et al.10).
bVariants possibly representing non-pathogenic polymorphisms (Ohtuska et al.6).
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nine alleles for p.Val37Ile, eight for c.235delC, one for p.[Gly45Glu;
Tyr136*], one for p.Arg143Trp, one for p.Ile71Thr and one for
p.Phe191Leu; p.Gly45Glu and p.Tyr136* mutations are on the same
parental allele.19 Among these mutations, the pathogenicity of
p.Ile71Thr and p.Phe191Leu has been controversial, and they are
considered to represent non-pathogenic polymorphisms.6 We also
found previously reported variants, p.Thr8Met and p.Arg127His, and
two novel variants, p.Cys60Tyr and p.Phe106Leu, which were not
included in the Invader assay-based mutation screening. The
pathogenicity of p.Thr8Met, and p.Arg127His variants is unknown.
We found 19 previously reported pathogenic variants, and 5
variants found in this study were unclassiﬁed, so the carrier frequency
of the GJB2 mutations is estimated to be at least 3.73–4.72%
(19–24/509). We believe that the screening (including the four
variants, p.Thr8Met, p.Ile71Thr, p.Arg127His and p.Phe191Leu, and
other novel variants) will be very important for more accurate genetic
testing. The pathogenicity of novel variants is not clear and requires
further studies for clariﬁcation.
The two novel variants mentioned above, p.Cys60Tyr and p.
Phe106Leu, and one silent variant, p.Val63Val (c.189G4T), were
identiﬁed in this study. Figure 1 shows amino acid sequences of Homo
sapiens and other species’ connexin26 and the two novel variants,
p.Cys60Tyr and p.Phe106Leu. Cys60 is evolutionarily conserved, while
the leucine residue of p.Phe106Leu is found in Xenopus laevis. To
predict the effect of the variants, we carried out computer analysis
using the Sorting Intolerant from Tolerant (SIFT: http://sift.jcvi.org/)
and Polymorphism Phenotyping (PolyPhen2: http://genetics.bwh.
harvard.edu/pph2/). The functional prediction of p.Cys60Tyr was
Damaging (1.0) by SIFT, and Damaging (1.0) by PolyPhen2. On the
other hand, that of p.Phe106Leu was Tolerated (0.23) by SIFT and
Benign (0) by PolyPhen2. Considering these data, p.Cys60Tyr is
expected to be pathogenic and p.Phe106Leu to be a non-pathogenic
polymorphism.
Synonymous variants are usually non-pathogenic unless the nucleo-
tide change alters the splicing of the RNA. Analysis of the p.Val63Val
(c.189G4T) synonymous variant using the prediction program
NNSPLICE (http://www.fruitﬂy.org/seq_tools/splice.html) indicates
that this variant is not expected to be either a donor or an acceptor
site for splicing and is, therefore, likely to be non-pathogenic. The
three subjects carrying p.Cys60Tyr, p.Phe106Leu or p.Val63Val had no
experience of hearing difﬁculty or tinnitus.
We found six alleles of the p.Thr123Asn mutation, but we did not
consider them to be pathogenic variants; p.Thr123Asn has been
considered to be a rare non-pathogenic variant because it was
found with equal frequency in patients and controls in Ohtsuka.6
In contrast, the non-pathogenic variants, p.Val27Ile, p.Glu114Gly and
p.Ile203Thr,11,15,20,21 that are frequently found in the Japanese
population6 were also frequently observed in this study. The most
common GJB2 mutation in Caucasian people, the c.35delG mutation,
was not found in these subjects, indicating differing variants among
ethnic groups. All things considered, the GJB2 carrier frequency in the
Japanese population was estimated to be at least 19/509 (3.73%). We
did not ﬁnd any subjects who carry homozygous or compound
heterozygous pathogenic mutations in this study.
DISCUSSION
There are several reports on carrier frequency and the mutation
spectrum of GJB2 mutations. In Europe, the carrier frequency of
c.35delG was reported to be around 2–3%.16,22,23 Green et al.,15
reported that 14 out of 560 general people carried the c.35delG
variant, so they estimated that the carrier rate of c.35delG was about
2.5% in the Midwestern USA.
In the Ashkenazi Jewish population, it was reported that the carrier
frequency of c.167delT variant was 4.03% (22/546).24 In the Thai
population, p.Val37Ile was the most frequent variant and the carrier
frequency of this variant was 17.1% (35/205)25 in healthy controls. In
the Korean population, the carrier frequency of p.Val37Ile was 1.35%
(28/2072), and that of c.235delC was 1.25% (26/2072), and no
c.35delG mutants were detected in their study.17
The majorities of studies have focused only on hearing-impaired
patients and their allele frequency and have not focused on the carrier
frequency. Ohtsuka et al.6 reported that the frequency of the mutant
alleles among hearing-impaired patients was 3.9% (96/2454) for the
c.235delC mutation, and 2.5% (61/2454) for the p.Val37Ile mutation.
Tsukada et al.19 reported that the mutation spectrum and frequency in
a large number of Japanese hearing-impaired patients, and the
c.235delC mutation allele frequency was 5.3% (142/2686), and that
of p.Val37Ile was 1.8% (47/2686).
In this study, we found eight alleles of the c.235delC mutant
(8/1018, 0.79%) and nine alleles of the p.Val37Ile mutant (9/1018,
0.88%) in the control population. Based on our observation, the carrier
frequency of c.235delC was 1.57% (8/509), and that of p.Val37Ile was
1.77% (9/509). In addition to these two most common mutations, we
found two other pathogenic variants (p.[Gly45Glu;Tyr136*], and p.
Arg143Trp) in this study, and the carrier frequency was estimated to be
around 3.73% (19/509). Furthermore, we identiﬁed two novel variants
(p.Cys60Tyr and p.Phe106Leu) whose pathogenic nature is unknown.
Amino-acid conservation information and prediction by computer
analysis (SIFT and PolyPhen2) indicated that p.Cys60Tyr may be
pathogenic and that p.Phe106Leu would be a non-pathogenic poly-
morphism. In addition to these prediction method, functional studies
would shed light on the pathogenesis on these variants.
In this study, we also detected two p.Thr8Met variants, one
p.Ile71Thr variant, one p.Arg127His variant and one p.Phe191Leu
variant, all with uncertain pathogenicity; p.Ile71Thr and p.Phe191Leu
were ﬁrst reported in Japanese patients.6 Ohtsuka et al.6 found four
p.Ile71Thr and four p.Phe191Leu variants in 2454 alleles, but
H. sapiens QPGCKNVCYDHYFP VAMHVAYRRHEKKRKFIKGEIKSEFKDIEEIK
M. musculus QPGCKNVCYDHHFP VAMHVAYRRHEKKRKFMKGEIKNEFKDIEEIK
R. norvegicus QPGCKNVCYDHYFP VAMHVAYRRHEKKRKFMKGEIKNEFKDIEEIK
X. laevis QPGCKNVCYDHHFP VAMHVAYLKHEEKRQLQKKGTFGGKDLEELK
D.rerio QPGCNSVCYDHFFP VAMH IAHRRHIDKKLYRQAGRTSPKDLEAIK
↑ p.Cys60Tyr ↑ p.Phe106Leu
Functional prediction of  p.Cys60Tyr and p.Phe106Leu
p.Cys60Tyr p.Phe106Leu
SIFT Damaging (1.0) Tolerated (0.23)
PolyPhen2 Damaging (1.0) Benign (0.00)
Figure 1 Alignment of amino-acid sequences of human and other species’
connexin26 (Cx26) showing the mutation sites of two novel variants,
p.Cys60Tyr and p.Phe106Leu, and functional prediction of p.Cys60Tyr and
p.Phe106Leu. We found two novel variants p.Cys60Tyr and p.Phe106Leu.
To predict their pathogenesis, we compared amino-acid sequences of human
and other species’ Cx26. As Cys60 is evolutionarily conserved, p.Cys60Tyr
could be pathogenic; p.Phe106Leu is probably a non-pathogenic
polymorphism because Xenopus has a leucine at this position. The
functional prediction of p.Cys60Tyr was Damaging (1.0) by SIFT, and
Damaging (1.0) by PolyPhen2. That of p.Phe106Leu was Tolerated (0.23)
by SIFT and Benign (0) by PolyPhen2. Prediction by SIFT and PolyPhen2
also showed that p.Cys60Tyr would be pathogenic and p.Phe106Leu would
be a non-pathogenic polymorphism.
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p.Ile71Thr and p.Phe191Leu were only found to be heterozygous with
no other mutations being detectable; therefore, it remains a possibility
that they were non-pathogenic rare polymorphisms. To date, the
pathogenicity of p.Ile71Thr and p.Phe191Leu mutations has not been
proven,6,19 so they may be non-pathogenic variants. The functional
prediction of p.Ile71Thr was Damaging (1.0) by SIFT and Damaging
(0.972) by PolyPhen2. That of p.Phe191Leu was Damaging (0.99) by
SIFT and Damaging (1.0) by PolyPhen2. The p.Thr8Met variant was
ﬁrst reported by Kenna et al.26 from hearing loss patients in the US
population, and it was also reported to be found in hearing-impaired
patients in Japan.9,19 The functional prediction of p.Thr8Met was
Damaging (0.97) by SIFT and Possibly Damaging (0.775)
by PolyPhen2. The pathogenesis of the p.Arg127His variant is
controversial17 as this variant was detected in one family with
congenital deafness22 but the variant was found in a homozygous
state in individuals with normal hearing in another study.27 In
addition this variant was predicted to be Tolerated (0.85) by SIFT
and Benign (0.001) by PolyPhen2. Considering these prediction
analyses, p.Thr8Met, p.Ile71Thr and p.Phe191Leu could be
pathogenic.
The carrier frequency and mutation spectrum of the Japanese
population was different from those of Caucasian populations; the
carrier frequency of c.35delG and c.235delC mutation is reported to be
2–3% and 0% in Caucasian,15,16,22,23 whereas 0% and 1.57% in the
present study, respectively. In addition, p.Val37Ile is revealed to
be common in Asian countries; the carrier frequency was 1.77%
in Japanese, 1.35% in Korea and 17.1% in Thai population,
respectively.17,25 In patients with impaired hearing, GJB2 mutations
were reported to have a phenotype–genotype correlation.18,19 For
example, the c.235delC homozygous mutation and the c.235delC/p.
Arg143Trp compound heterozygous mutation show severe hearing
impairment, while the p.Val37Ile homozygous mutation has a mild
phenotype.19
Among hearing-impaired patients in Japan, the c.235delC mutation
is reported to be the most prevalent mutation.5,6,20 However, in people
with normal hearing, the p.Val37Ile mutation was more frequent than
c.235delC in our study, as with previous studies.19 This apparent
contradiction may be because patients with the p.Val37Ile mutation
have a milder phenotype and may therefore be excluded from the
research on hearing loss.19
Generally, in the case of autosomal recessive diseases, if the parents
are related, the probability of a homozygous mutant allele increases.
However, even if the parents are not related, it is still possible for both
to be GJB2 mutation carriers because the GJB2 carrier frequency is
estimated to be as high as around 3.7%.
In conclusion, we estimate that the GJB2 carrier frequency of the
Japanese population would be about 3.7%. Almost half of these would
have the p.Val37Ile mutation, whereas individuals homozygous for
this mutation have a relative mild phenotype. The other major
mutation allele would be c.235delC. Our study is the latest and the
largest report on carrier frequencies of GJB2 mutations in the Japanese
general population to date. This is indispensable information for
predicting the next generation’s incidence of hearing difﬁculty. We
believe that information from this study will be useful in genetic
counseling in Japan.
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